The Pharmome Map: A Comprehensive Public Dataset for Drug-Target Interaction Modeling

Why It Matters

A near‑complete drug‑target activity matrix dramatically speeds AI‑driven discovery and safety assessment, giving pharma and academia a shared, high‑quality foundation for innovation.

Key Takeaways

• 1,397 FDA drugs screened across three major target families
• Dataset publicly available, updated every two months
• Covers >50% of small‑molecule drug targets
• Enables AI modeling of polypharmacology and adverse events
• 2026 expansion will triple GPCR and kinase coverage

Pulse Analysis

The pharmaceutical landscape has long suffered from a fragmented view of drug‑target interactions, with most databases offering only primary targets and a handful of off‑targets. This sparsity hampers predictive modeling, safety profiling, and the identification of novel therapeutic opportunities. By delivering quantitative activity measurements for every combination of 1,397 approved small molecules and three high‑impact target classes, the pharmome map fills a critical data void, creating a dense matrix that researchers can treat as a reliable foundation for computational studies.

EvE Bio’s approach emphasizes consistency and scalability. Nuclear receptors are profiled with biochemical co‑factor recruitment assays, GPCRs with cell‑based agonist/antagonist screens, and protein kinases with competition‑based inhibition assays. All assays follow a single‑format pipeline, ensuring comparable readouts across classes. The bi‑monthly public releases, coupled with detailed metadata, make the dataset immediately usable for machine‑learning pipelines, from structure‑activity relationship models to adverse‑event prediction engines. Its open‑access nature also encourages community‑driven validation and extension.

The implications extend beyond academic curiosity. Pharma companies can leverage the map to de‑risk pipelines by spotting hidden off‑target liabilities early, while clinicians may gain insights into polypharmacy effects through comprehensive activity profiles. Regulatory bodies could use the data to refine safety surveillance frameworks. With a planned 2026 expansion that will triple GPCR and kinase coverage and introduce biased‑signaling measurements, the pharmome map is poised to become an indispensable resource for next‑generation drug discovery and precision medicine.